Tropomyosin-related kinase B inhibitor has potential for tumor regression and relapse prevention in pulmonary large cell neuroendocrine carcinoma

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3699-3704

  Odate, Seiichi ^a   Onishi, Hideya ^a   Nakamura, Katsuya ^a   Kojima, Masayuki ^b   Uchiyama, Akihiko ^c   Kato, Masato ^d   Katano, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA RED CROSS HOSPITAL   (Japan)

^c KYUSHU KOSEI NENKIN HOSPITAL   (Japan)

^d HAMANOMACHI HOSPITAL   (Japan)

Author keywords

BDNF; Invasion; Large cell neuroendocrine carcinoma; Lung cancer; TRKB; Tumorigenicity

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GELATINASE A; GELATINASE B; K 252A; SODIUM CHLORIDE; TROPOMYOSIN; TROPOMYOSIN RELATED KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RECURRENCE; CARCINOGENICITY; CONTROLLED STUDY; FEMALE; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG CANCER; MOUSE; NONHUMAN; PLEURA CAVITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

BDNF; INVASION; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG CANCER; TRKB; TUMORIGENICITY;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CARBAZOLES; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; CELL LINE, TUMOR; FEMALE; HUMANS; INDOLE ALKALOIDS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RECURRENCE;

EID: 84885009182     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, Yokose T, Jiang SX, Inoue T, Nakagawa K, Tajima K and Nagai K: Neuroendocrine neoplasms of the lung: A prognostic spectrum. J Clin Oncol 24: 70-76, 2006.
3. Matsumoto K, Wada RK, Yamashiro JM, Kaplan DR and Thiele CJ: Expression of brain-derived neurotrophic factor and pl4S TRKB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res 55: 1798-1806, 1995.
4. Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D and Isaacs JT: Cell cycle-independent death of prostate adenocarcinoma is induced by the TRK tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 4: 1887-1898, 1998.
5. Miknyoczki SJ, Lang D, Huang L, Klein-Szanto AJ, Dionne CA and Ruggeri BA: Neurotrophins and TRK receptors in human pancreatic ductal adenocarcinoma: Expression patterns and effects on in vitro invasive behavior. Int J Cancer 81: 417-427, 1999.
6. Au CW, Siu MK, Liao X, Wong ES, Ngan HY, Tam KF, Chan DC, Chan QK and Cheung AN: Tyrosine kinase B receptor and BDNF expression in ovarian cancers-Effect on cell migration, angiogenesis and clinical outcome. Cancer Lett 281: 151-161, 2009.
7. Odate S, Nakamura K, Onishi H, Kojima M, Uchiyama A, Nakano K, Kato M, Tanaka M and Katano M: TRKB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma. Lung Cancer 79: 205-214, 2013.
8. Miknyoczki SJ, Dionne CA, Klein-Szanto AJ and Ruggeri BA: The novel TRK receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness. Ann NY Acad Sci 880: 252-262, 1999.
9. Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, Groshen S, Hellriegel ET, Bensen-Kennedy D, Matthay KK, Brodeur GM and Maris JM: Phase I trial of lestaurtinib for children with refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol 68: 1057-1065, 2011.
10. Iyer R, Evans AE, Qi X, Ho R, Minturn JE, Zhao H, Balamuth N, Maris JM and Brodeur GM: Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. Clin Cancer Res 16: 1478-1485, 2010.
11. Kawamura N, Kawamura K, Manabe M and Tanaka T: Inhibition of brain-derived neurotrophic factor/tyrosine kinase B signaling suppresses choriocarcinoma cell growth. Endocrinology 151: 3006-3014, 2010.
12. Kai M, Onishi H, Souzaki M, Tanaka H, Kubo M, Tanaka M and Katano M: Semi-quantitative evaluation of CD44(+)/CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method. Cancer Sci 102: 2132-2138, 2011.
13. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: Biologic activity and clinical implications. Int J Oncol 18: 1135-1149, 2000.